What the trial was testing
The SABO enrolled 288 patients with obesity. The study was sponsored by Spatz FGIA, Inc and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
Researchers followed patients through treatment and into recovery, tracking the outcomes that mattered most for the disease being studied.
What the results showed
People with the adjustable balloon lost 15% of their body weight on average over 32 weeks.
Lancet (London, England) · 2021 · NCT02812160
These findings — that people lost 15% of their weight with the balloon versus 3% with lifestyle changes alone — were published in the Lancet (London, England) and represent the headline result of the study.
Researchers tracked outcomes across 288 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with obesity, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This adjustable stomach balloon is FDA-approved and available now. The balloon stays in your stomach for about 8 months and can be made larger or smaller through a quick procedure. Talk to your doctor about whether this option fits your weight loss goals.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open obesity trials
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
This is a single center randomized double blind controlled study of patients (BMI ≥ 27 kg/m2) with obesity and Atrial Fibrillation (AFIB) randomized to Tirzepatide vs. placebo. It is expected that the significant weight loss with Tirzepatide will result in improved control, management, symptom severity, and burden of AFIB at 12 months.
Impact of Dietary Phosphate Excess on Exercise Capacity and Visceral Adiposity
Studies in mice demonstrated that dietary phosphate (Pi) loading that mimic the level of US adult consumption leads to reduced spontaneous locomotor activity, exercise capacity, and reduced resting metabolic rate when in normal mice by impairing skeletal muscle mitochondrial function and fat oxidation. However, relevance of this findings in humans remains unknown.